<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>國外罕見／孤兒藥相關法規比較（修訂版）</title>
    <meta name="description" content="美國、歐盟、日本、加拿大、澳洲及台灣罕見疾病 / 孤兒藥制度修訂版對照，含最新定義、獎勵措施、修正標註與來源。">
    <meta data-version="1.1" data-last-updated="2025-09-09">
    <style>
        :root {
            --c-primary:#2563eb;
            --c-secondary:#0d6efd;
            --c-bg:#f5f7fa;
            --c-border:#e2e8f0;
            --c-danger:#dc3545;
            --c-warn:#f59e0b;
            --c-ok:#059669;
            --c-info:#0ea5e9;
            --c-muted:#64748b;
            --c-highlight:#fff8e1;
            --radius:10px;
        }
        body {
            font-family: "Microsoft JhengHei", Arial, sans-serif;
            margin:0;
            padding:20px;
            background:var(--c-bg);
            line-height:1.65;
            color:#1e293b;
        }
        .container {
            max-width:1450px;
            margin:0 auto;
            background:#fff;
            padding:32px 40px 60px;
            border-radius:var(--radius);
            box-shadow:0 6px 28px -8px rgba(0,0,0,.12);
            position:relative;
        }
        h1 {
            margin:0 0 28px;
            text-align:center;
            font-size:2.2rem;
            background:linear-gradient(135deg,var(--c-primary),#0ea5e9);
            -webkit-background-clip:text;
            color:transparent;
        }
        .meta-bar {
            display:flex;
            flex-wrap:wrap;
            gap:16px;
            font-size:.85rem;
            background:#eff6ff;
            border:1px solid #bfdbfe;
            padding:10px 16px;
            border-radius:var(--radius);
            margin-bottom:25px;
        }
        .badge {
            display:inline-block;
            padding:3px 10px 4px;
            font-size:.7rem;
            letter-spacing:.5px;
            border-radius:999px;
            background:#1d4ed8;
            color:#fff;
            margin-right:6px;
            vertical-align:middle;
        }
        .toc {
            background:#f1f5f9;
            border:1px solid var(--c-border);
            padding:22px 26px;
            border-radius:var(--radius);
            margin-bottom:38px;
            position:relative;
        }
        .toc h2 {
            margin:0 0 14px;
            font-size:1.25rem;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
        }
        .toc ul {
            list-style:none;
            padding:0;
            margin:0;
            columns:2;
        }
        .toc li {
            margin:6px 0;
            break-inside:avoid;
        }
        .toc a {
            text-decoration:none;
            color:var(--c-secondary);
            font-weight:500;
            position:relative;
            padding-left:4px;
        }
        .toc a:hover {
            text-decoration:underline;
            color:#1d4ed8;
        }
        .law-section {
            border:1px solid var(--c-border);
            border-radius:var(--radius);
            margin-bottom:55px;
            overflow:hidden;
            background:#ffffff;
        }
        .law-header {
            margin:0;
            padding:18px 24px;
            background:linear-gradient(120deg,#1e3a8a,#1d4ed8 50%,#2563eb);
            color:#fff;
            font-size:1.45rem;
            letter-spacing:.5px;
            display:flex;
            justify-content:space-between;
            flex-wrap:wrap;
            gap:12px;
        }
        .law-meta {
            background:#f8fafc;
            padding:14px 22px;
            font-size:.86rem;
            border-top:1px solid var(--c-border);
            border-bottom:1px solid var(--c-border);
            color:#475569;
            line-height:1.5;
        }
        .law-content {
            padding:30px 34px 40px;
        }
        .article {
            margin-bottom:32px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            border-left:5px solid var(--c-primary);
            border-radius:6px;
            padding:18px 22px 20px;
            position:relative;
        }
        .article-title {
            font-weight:600;
            font-size:1.05rem;
            margin:0 0 14px;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
            flex-wrap:wrap;
        }
        .article-title .small-label {
            background:#e0f2fe;
            color:#0369a1;
            font-size:.6rem;
            padding:2px 6px 3px;
            border-radius:4px;
            letter-spacing:.5px;
        }
        .bilingual-content {
            display:grid;
            grid-template-columns:1fr 1fr;
            gap:20px;
        }
        .original-text, .translation {
            padding:14px 16px 16px;
            border-radius:8px;
            font-size:.92rem;
            position:relative;
            line-height:1.55;
        }
        .original-text {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
        }
        .translation {
            background:#fffceb;
            border:1px solid #fde68a;
        }
        .lang-label {
            font-size:.65rem;
            font-weight:600;
            letter-spacing:.8px;
            color:#334155;
            background:#e2e8f0;
            padding:4px 8px;
            border-radius:999px;
            display:inline-block;
            margin-bottom:10px;
        }
        .highlight-box {
            background:#eef6ff;
            padding:18px 22px;
            border-left:6px solid #2563eb;
            border-radius:8px;
            margin:30px 0 10px;
            font-size:.93rem;
        }
        .highlight-box h3 {
            margin:0 0 14px;
            font-size:1rem;
            color:#1e3a8a;
            letter-spacing:.5px;
        }
        .point-list {
            margin:0;
            padding:0;
            list-style:none;
            display:grid;
            gap:10px;
        }
        .point-item {
            position:relative;
            padding-left:18px;
        }
        .point-item:before {
            content:"◆";
            font-size:.6rem;
            color:#2563eb;
            position:absolute;
            left:0;
            top:4px;
        }
        .comparison-wrapper {
            overflow-x:auto;
            margin-top:10px;
        }
        table.comparison-table {
            width:100%;
            border-collapse:collapse;
            font-size:.85rem;
            min-width:1100px;
        }
        .comparison-table th, .comparison-table td {
            border:1px solid #e2e8f0;
            padding:10px 10px;
            text-align:left;
            vertical-align:top;
        }
        .comparison-table th {
            background:#1e3a8a;
            color:#ffffff;
            position:sticky;
            top:0;
            z-index:2;
            font-weight:600;
            letter-spacing:.5px;
        }
        .comparison-table tbody tr:nth-child(even) {
            background:#f8fafc;
        }
        .comparison-table td .note-inline {
            display:block;
            font-size:.7rem;
            color:#64748b;
            margin-top:4px;
            line-height:1.3;
        }
        .status-tag {
            display:inline-block;
            font-size:.6rem;
            padding:3px 6px 4px;
            font-weight:600;
            letter-spacing:.5px;
            border-radius:4px;
            margin-left:6px;
            vertical-align:middle;
        }
        .tag-updated { background:#d1fae5; color:#047857; }
        .tag-corrected { background:#fef3c7; color:#b45309; }
        .tag-removed { background:#fee2e2; color:#b91c1c; }
        .tag-new { background:#e0f2fe; color:#0369a1; }
        .updated, .corrected, .removed, .added {
            padding:2px 4px;
            border-radius:4px;
            font-size:.85em;
            font-weight:500;
        }
        .updated { background:#dcfce7; }
        .corrected { background:#fef9c3; }
        .removed { background:#fee2e2; text-decoration:line-through; }
        .added { background:#e0f2fe; }
        .footnotes {
            background:#f8fafc;
            border:1px solid var(--c-border);
            padding:24px 28px 30px;
            border-radius:var(--radius);
            font-size:.78rem;
            line-height:1.45;
            margin-top:60px;
        }
        .footnotes h3 {
            margin:0 0 14px;
            font-size:.95rem;
            color:#0f172a;
        }
        .footnotes ol {
            margin:0;
            padding-left:18px;
        }
        .footnotes li { margin:6px 0; }
        .callout {
            border:1px solid #cbd5e1;
            background:#ffffff;
            padding:16px 18px;
            border-radius:8px;
            margin:24px 0;
            display:flex;
            gap:14px;
            font-size:.9rem;
            position:relative;
        }
        .callout.info { border-color:#93c5fd; background:#eff6ff; }
        .callout.warn { border-color:#fcd34d; background:#fffbeb; }
        .callout.danger { border-color:#fca5a5; background:#fef2f2; }
        .callout strong { color:#0f172a; }
        .legend {
            display:flex;
            flex-wrap:wrap;
            gap:10px;
            margin:14px 0 4px;
            font-size:.65rem;
        }
        .legend span {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            padding:4px 8px;
            border-radius:6px;
            display:flex;
            align-items:center;
            gap:4px;
        }
        .legend code {
            background:#e2e8f0;
            padding:2px 4px;
            border-radius:4px;
            font-size:.65rem;
        }
        .revision-log {
            margin-top:55px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            padding:20px 24px 26px;
            border-radius:var(--radius);
        }
        .revision-log h3 {
            margin:0 0 12px;
            font-size:1rem;
        }
        .revision-log ul {
            margin:0;
            padding-left:18px;
            font-size:.85rem;
            line-height:1.5;
        }
        .source-links {
            display:grid;
            gap:14px;
            grid-template-columns:repeat(auto-fill,minmax(260px,1fr));
            margin-top:14px;
        }
        .source-card {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            border-radius:8px;
            padding:12px 14px 14px;
            font-size:.7rem;
            line-height:1.35;
            position:relative;
        }
        .source-card h4 {
            margin:0 0 6px;
            font-size:.75rem;
            color:#0f172a;
        }
        .source-card a {
            word-break:break-all;
            color:#1d4ed8;
            text-decoration:none;
        }
        .source-card a:hover {
            text-decoration:underline;
        }
        .disclaimer {
            margin-top:60px;
            padding:20px 24px;
            background:#fef2f2;
            border:1px solid #fecaca;
            border-radius:var(--radius);
            font-size:.78rem;
            line-height:1.5;
            color:#991b1b;
        }
        .back-to-top {
            position:fixed;
            right:26px;
            bottom:26px;
            width:50px;
            height:50px;
            background:#2563eb;
            color:#fff;
            border:none;
            border-radius:50%;
            cursor:pointer;
            font-size:18px;
            display:none;
            box-shadow:0 4px 16px -4px rgba(0,0,0,.35);
            transition:.25s;
        }
        .back-to-top:hover { background:#1d4ed8; transform:translateY(-3px); }
        mark {
            background:#fde68a;
            padding:1px 3px;
            border-radius:4px;
        }
        @media (max-width:980px) {
            .bilingual-content { grid-template-columns:1fr; }
            .toc ul { columns:1; }
            .law-content { padding:26px 22px 30px; }
            .article { padding:16px 16px 18px; }
            h1 { font-size:1.85rem; }
        }
        @media (max-width:600px) {
            body { padding:12px; }
            .container { padding:22px 20px 50px; }
            .law-header { font-size:1.15rem; }
        }
    </style>
</head>
<body>
  <div class="container">
    <h1>🌐 國外罕見／孤兒藥法規現況對照（修訂版）</h1>

    <div class="meta-bar">
      <div><span class="badge">VERSION</span> 1.1 修訂版</div>
      <div><span class="badge" style="background:#059669;">更新日期</span> 2025-09-09</div>
      <div><span class="badge" style="background:#0ea5e9;">覆蓋範圍</span> 台灣 / 美國 / 歐盟 / 日本 / 加拿大 / 澳洲</div>
      <div><span class="badge" style="background:#9333ea;">語言</span> 中英 / 日文原文節錄</div>
    </div>

    <div class="callout info">
      <div><strong>說明：</strong>本檔為您原始版本之「糾錯 + 更新 + 來源標註」修訂版。保留原結構，對不正確或過時內容以標籤與行內標註 (<span class="corrected">修正</span> / <span class="removed">移除</span> / <span class="updated">更新</span>) 表示；新增補充以 <span class="added">新增</span> 顯示。</div>
    </div>

    <div class="legend">
      <span><code>updated</code> = 更新數據</span>
      <span><code>corrected</code> = 修正文義/事實</span>
      <span><code>removed</code> = 刪除或標記錯誤原述</span>
      <span><code>added</code> = 新增補充</span>
    </div>

    <div class="toc">
      <h2>📋 目錄</h2>
      <ul>
        <li><a href="#usa-orphan-drug-act">一、美國孤兒藥法 (Orphan Drug Act)</a></li>
        <li><a href="#eu-orphan-regulation">二、歐盟孤兒藥規則 (Reg. 141/2000)</a></li>
        <li><a href="#japan-intractable-disease-act">三、日本《難病法》與指定難病制度</a></li>
        <li><a href="#canada-rare-strategy">四、加拿大罕見疾病策略現況</a></li>
        <li><a href="#australia-orphan-program">五、澳洲 TGA 孤兒藥制度</a></li>
        <li><a href="#comparison-table">六、修訂後比較表</a></li>
        <li><a href="#sources">七、來源與參考連結</a></li>
        <li><a href="#revision-log">八、修訂紀錄</a></li>
        <li><a href="#disclaimer">九、免責聲明</a></li>
      </ul>
    </div>

    <!-- USA -->
    <section id="usa-orphan-drug-act" class="law-section">
      <h2 class="law-header">一、美國孤兒藥法 Orphan Drug Act (ODA)</h2>
      <div class="law-meta">
        制定：1983年 | 主管機關：FDA OOPD | 最新主要變動：<span class="updated">2017 稅制改革影響研發抵免比例</span>
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Section 526 - Designation 核心摘要 <span class="small-label">原意保留</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Manufacturer or sponsor may request designation if the drug is intended for a rare disease or condition and either (A) prevalence <200,000 persons in the US OR (B) no reasonable expectation of recovering development costs.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              製造商/申請人可申請指定；條件為：用於罕見疾病，且 (A) 患者 <20 萬人，或 (B) 無法合理回收開發成本。
            </div>
          </div>
        </div>

          <div class="article">
            <div class="article-title">Section 527 - 7 年市場獨占 <span class="small-label">保留</span></div>
            <div class="bilingual-content">
              <div class="original-text">
                <div class="lang-label">EN</div>
                Upon approval for an orphan-designated indication, FDA shall not approve the same drug for the same use for 7 years (except statutory exceptions).
              </div>
              <div class="translation">
                <div class="lang-label">中文</div>
                獲得孤兒適應症核准後，於 7 年內 FDA 不再核准同藥同適應症（法定例外除外）。
              </div>
            </div>
          </div>

          <div class="highlight-box">
            <h3>美國重點與更新</h3>
            <ul class="point-list">
              <li class="point-item">罕見疾病定義：<strong><200,000 人</strong> 或無法回收成本（21 U.S.C. §360bb）</li>
              <li class="point-item">市場獨占：7 年（不等同資料保護，可疊加 Pediatric Exclusivity 6 個月）</li>
              <li class="point-item">稅收抵免：<span class="removed">50%</span> → <span class="corrected">現行約 25%（TCJA 後）</span></li>
              <li class="point-item"><span class="added">激勵項：免/減使用者費、Protocol Assistance、Grant Program (FDA OOPD)</span></li>
            </ul>
          </div>

      </div>
    </section>

    <!-- EU -->
    <section id="eu-orphan-regulation" class="law-section">
      <h2 class="law-header">二、歐盟孤兒藥規則 Regulation (EC) No 141/2000</h2>
      <div class="law-meta">
        生效：2000年 | 主管：EMA COMP | 兒科完成可延長至 12 年（與 Paediatric Regulation 聯動）
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Article 3 - 指定條件 摘要 <span class="small-label">保留</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              (a) Life‑threatening or chronically debilitating & prevalence ≤5 in 10,000 OR (b) insufficient return without incentives; AND (c) no satisfactory method or significant benefit over existing.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              (a) 威脅生命 / 長期衰弱 且 盛行率 ≤5/10,000，或 (b) 無獎勵無足夠回報；且 (c) 無滿意療法或具顯著效益。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>歐盟重點與補充</h3>
          <ul class="point-list">
            <li class="point-item">盛行率門檻：≤5/10,000（以 EU 總人口推估）</li>
            <li class="point-item">市場獨占：10 年；<span class="added">第 6 年起若喪失「significant benefit」或供應不足可削減</span></li>
            <li class="point-item"><span class="added">兒科計畫完成：可延長至 12 年（Reg. (EC) 1901/2006）</span></li>
            <li class="point-item">激勵：集中審查、費用減免、中小企業 (SME) 支持</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Japan -->
    <section id="japan-intractable-disease-act" class="law-section">
      <h2 class="law-header">三、日本《難病法》與「指定難病」制度</h2>
      <div class="law-meta">
        法律：2014 制定 / 2015 施行 | 主管：厚生労働省 | 制度重點：醫療費助成 + 研究推進
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">指定難病 主要要件 <span class="small-label">修正</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">原文節義</div>
              病因未解、無根治療法、長期療養、患者數低、客觀診斷基準成立。
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              日本現行指定難病考量五要素：① 發病機序不明 ② 無確立治癒療法 ③ 長期療養需要 ④ 患者數低（約 <span class="corrected">人口 0.1%</span> 門檻水準，用於政策判斷，非僅早期「5萬人」單一數字）⑤ 有客觀診斷基準。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>日本重點</h3>
          <ul class="point-list">
            <li class="point-item"><span class="removed">「患者少於5萬人」單一表述</span> → <span class="corrected">改為政策實務綜合門檻（約人口 0.1%）並結合其他條件</span></li>
            <li class="point-item">醫療費助成：符合所得與重症分類者部分負擔減免</li>
            <li class="point-item">重視：客觀診斷標準 & 研究登錄（難病情報中心）</li>
            <li class="point-item"><span class="added">與傳統「孤兒藥專屬市場獨占」概念不同，偏重患者保障與研究網絡</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Canada -->
    <section id="canada-rare-strategy" class="law-section">
      <h2 class="law-header">四、加拿大罕見疾病策略（非專法）</h2>
      <div class="law-meta">
        現況：無正式「孤兒藥法」 | 策略：2023 National Strategy for Drugs for Rare Diseases（10 億加元 / 3 年）
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">制度現況 <span class="small-label">修正</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">原描述</div>
              <span class="removed">2019年實施 Orphan Drug Framework；定義 <1/2000；市場獨占 8 年。</span>
            </div>
            <div class="translation">
              <div class="lang-label">修訂</div>
              <span class="corrected">加拿大尚未完成孤兒藥專法立法。8 年資料保護屬一般創新藥規則（非孤兒專屬）。「<1/2,000」僅為部分評估參考，無硬性法規門檻。2023 年啟動全國資助策略，聚焦加速可及、協調 HTA / 定價與資料共享。</span>
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>加拿大重點</h3>
          <ul class="point-list">
            <li class="point-item">缺乏統一法定罕見疾病定義（多機構採個案與國際參考）</li>
            <li class="point-item">激勵相對弱於美/歐；依賴泛用資料保護（8 年 + 可能 6 個月兒科）</li>
            <li class="point-item"><span class="added">策略重點：公平可及、統一 HTA、資料互通、患者參與</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Australia -->
    <section id="australia-orphan-program" class="law-section">
      <h2 class="law-header">五、澳洲 TGA 孤兒藥制度</h2>
      <div class="law-meta">
        計畫創立：1998（2017 改版） | 主管：TGA | 核心：費用減免 + 指定程序
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">指定條件 <span class="small-label">修正</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">原描述</div>
              <span class="removed">少於 2,000 人；5 年市場獨占。</span>
            </div>
            <div class="translation">
              <div class="lang-label">修訂</div>
              <span class="corrected">現行採用：盛行率 <5/10,000（對齊 EU 門檻）或經證明在缺乏激勵下商業不可行。無專屬孤兒「市場獨占期」，重點為費用減免與監管協助。</span>
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>澳洲重點</h3>
          <ul class="point-list">
            <li class="point-item">費用減免（評估 / 申請費）</li>
            <li class="point-item">無獨立 Orphan Exclusivity 條款</li>
            <li class="point-item">可併用優先審評 (Priority/Limited evaluation) 規格（條件不同）</li>
            <li class="point-item"><span class="added">聚焦小型市場科學與費用障礙降低</span></li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Comparison Table -->
    <section id="comparison-table" class="law-section">
      <h2 class="law-header">六、各司法轄區比較（修訂後）</h2>
      <div class="law-content">

        <div class="comparison-wrapper">
          <table class="comparison-table">
            <thead>
              <tr>
                <th>項目</th>
                <th>台灣</th>
                <th>美國</th>
                <th>歐盟</th>
                <th>日本</th>
                <th>加拿大</th>
                <th>澳洲</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><strong>法律 / 制度名稱</strong></td>
                <td>罕見疾病防治及藥物法</td>
                <td>Orphan Drug Act</td>
                <td>Reg. 141/2000</td>
                <td>難病法 + 指定難病制度</td>
                <td><span class="corrected">無專法（2023 罕見疾病策略）</span></td>
                <td>TGA Orphan Drug Program</td>
              </tr>
              <tr>
                <td><strong>罕見/指定門檻</strong></td>
                <td>盛行率 ≤1/10,000</td>
                <td><200,000 人或成本不可回收</td>
                <td>≤5/10,000</td>
                <td><span class="corrected">綜合條件（含患者數約 <0.1% 人口 + 其他要件）</span><span class="note-inline">非單一固定數字</span></td>
                <td><span class="corrected">無統一定義（參考國際門檻）</span></td>
                <td><span class="corrected"><5/10,000 或無商業可行性</span></td>
              </tr>
              <tr>
                <td><strong>市場獨占 / 排他</strong></td>
                <td><span class="corrected">無典型 Orphan Exclusivity；提供資料保護/給付支持</span></td>
                <td>7 年 Orphan Exclusivity</td>
                <td>10 年（可縮短 / 兒科至 12 年）</td>
                <td>無孤兒專屬獨占（醫療費助成）</td>
                <td>無（一般新藥 8 年資料保護）</td>
                <td><span class="corrected">無專屬孤兒獨占；費用減免</span></td>
              </tr>
              <tr>
                <td><strong>稅務 / 財政激勵</strong></td>
                <td>部分研發/投資抵減（產創條例）</td>
                <td><span class="corrected">臨床研發抵免 25%</span></td>
                <td>Member State 自訂（部份減免）</td>
                <td>研究補助 / 助成金</td>
                <td>有限（專案式）</td>
                <td>無專屬稅務；費用減免</td>
              </tr>
              <tr>
                <td><strong>審查費用減免</strong></td>
                <td>有</td>
                <td>有（User Fee 減免/豁免）</td>
                <td>有（Protocol Assistance 優惠）</td>
                <td>有</td>
                <td>部分情況</td>
                <td>有（指定後大幅減免）</td>
              </tr>
              <tr>
                <td><strong>優先 / 加速審查</strong></td>
                <td>有（快速審查機制）</td>
                <td>Priority Review / Fast Track / Breakthrough 可疊加</td>
                <td>可集中審評 + PRIME</td>
                <td>個案處理</td>
                <td>個案（Priority Review）</td>
                <td>Priority / Provisional / Orphan 支援</td>
              </tr>
              <tr>
                <td><strong>資料 / 兒科延長</strong></td>
                <td>資料保護按藥品法一般規範</td>
                <td>Pediatric 延長 6 個月（若合格）</td>
                <td>兒科可延長至 12 年</td>
                <td>無 Orphan 專屬延長</td>
                <td>8 年 + 6 個月（兒科）</td>
                <td>按一般藥品規則</td>
              </tr>
              <tr>
                <td><strong>醫療 / 費用支持</strong></td>
                <td>健保 + 特定補助</td>
                <td>有限（州 / 保險差異）</td>
                <td>會員國自訂</td>
                <td>醫療費助成制度健全</td>
                <td>省級差異 / 策略資助</td>
                <td>公共資助有限</td>
              </tr>
              <tr>
                <td><strong>患者資料登錄</strong></td>
                <td>逐步建立（疾管署/研究計畫）</td>
                <td>多重登錄 / NIH / 自願性</td>
                <td>歐盟網絡 / Orphanet</td>
                <td>指定難病登錄制度</td>
                <td>分散式 / 專題計畫</td>
                <td>分散 / 專業學會</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout warn">
          <strong>解讀提示：</strong>各國「市場獨占」法律性質並非完全可比；須區分「法定排他」與「資料保護 / 行政激勵」。
        </div>

      </div>
    </section>

    <!-- Sources -->
    <section id="sources" class="law-section">
      <h2 class="law-header">七、來源與參考連結</h2>
      <div class="law-content">

        <div class="source-links">
          <div class="source-card">
            <h4>美國 Orphan Drug Act</h4>
            <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360bb" target="_blank">21 U.S.C. §360bb–360dd</a>
          </div>
          <div class="source-card">
            <h4>FDA Orphan 資料庫</h4>
            <a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/" target="_blank">OOPD Listing</a>
          </div>
          <div class="source-card">
            <h4>Tax Cuts and Jobs Act</h4>
            <a href="https://www.congress.gov/bill/115th-congress/house-bill/1" target="_blank">TCJA 2017</a>
          </div>
          <div class="source-card">
            <h4>EU Reg. 141/2000</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32000R0141" target="_blank">EUR-Lex 141/2000</a>
          </div>
          <div class="source-card">
            <h4>EU Orphan Guidance</h4>
            <a href="https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation" target="_blank">EMA Orphan Page</a>
          </div>
          <div class="source-card">
            <h4>兒科規則</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32006R1901" target="_blank">Reg. (EC) 1901/2006</a>
          </div>
          <div class="source-card">
            <h4>日本 難病法</h4>
            <a href="https://elaws.e-gov.go.jp/document?lawid=426AC0000000050" target="_blank">e-Gov 法令</a>
          </div>
          <div class="source-card">
            <h4>日本 指定難病</h4>
            <a href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000084783.html" target="_blank">厚生労働省</a>
          </div>
          <div class="source-card">
            <h4>加拿大策略新聞稿</h4>
            <a href="https://www.canada.ca/en/health-canada/news/2023/03/supporting-canadians-with-rare-diseases.html" target="_blank">2023 Strategy</a>
          </div>
          <div class="source-card">
            <h4>擬議孤兒藥政策背景</h4>
            <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/initiatives/orphan-drugs.html" target="_blank">Health Canada</a>
          </div>
          <div class="source-card">
            <h4>澳洲 Orphan 指南</h4>
            <a href="https://www.tga.gov.au/resources/resource/guidance/orphan-drug-designation" target="_blank">TGA Guidance</a>
          </div>
          <div class="source-card">
            <h4>澳洲 費用減免</h4>
            <a href="https://www.tga.gov.au/how-we-regulate/fees/orphan-drugs" target="_blank">TGA Fees</a>
          </div>
          <div class="source-card">
            <h4>台灣 法規</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020037" target="_blank">罕見疾病防治及藥物法</a>
          </div>
          <div class="source-card">
            <h4>台灣 衛福部</h4>
            <a href="https://www.mohw.gov.tw" target="_blank">MOHW 官網</a>
          </div>
          <div class="source-card">
            <h4>Orphanet / 國際</h4>
            <a href="https://www.orpha.net" target="_blank">Orphanet</a>
          </div>
          <div class="source-card">
            <h4>NORD</h4>
            <a href="https://rarediseases.org/" target="_blank">NORD</a>
          </div>
          <div class="source-card">
            <h4>EURORDIS</h4>
            <a href="https://www.eurordis.org/" target="_blank">EURORDIS</a>
          </div>
        </div>

        <div class="footnotes">
          <h3>註釋（Footnotes）</h3>
          <ol>
            <li>美國稅收抵免：2017 以前最高 50%，Tax Cuts and Jobs Act 後改為 25% 上限。</li>
            <li>日本「患者數」並非唯一門檻，政策文件以「人口約 0.1% 以下」作參考階層。</li>
            <li>加拿大尚無定法定盛行率，HTA 與策略層面案例式處理。</li>
            <li>澳洲 2017 後採對齊 EU 的盛行率邏輯（<5/10,000），廢除舊有固定人數式表述。</li>
            <li>歐盟市場獨占可因「充分供應 / significant benefit 喪失」被削減，兒科可延長。</li>
            <li>「市場獨占」與「資料保護」：兩者法律效果與適用範圍不同，需避免混用。</li>
          </ol>
        </div>

      </div>
    </section>

    <!-- Revision Log -->
    <section id="revision-log" class="revision-log">
      <h3>八、修訂紀錄</h3>
      <ul>
        <li><strong>v1.1 (2025-09-09)：</strong>修正美國稅收抵免數據；日本指定難病條件改為多要素；加拿大改為策略描述；澳洲定義改為 <5/10,000；刪除不實「5 年市場獨占」；比較表重構。</li>
        <li><strong>v1.0 (原始版本)：</strong>含過時與錯誤數據（稅收 50%、日本 5 萬人、澳洲 2,000 人等）。</li>
      </ul>
    </section>

    <!-- Disclaimer -->
    <section id="disclaimer" class="disclaimer">
      <strong>免責聲明：</strong>本文件為教育與政策研究參考用途，非法律意見。正式適用應以各司法轄區主管機關最新公布、官方公報與原文法規為準。對於基於本文採取之任何行動，請先諮詢專業法律與法規事務顧問。
    </section>

  </div>

  <button class="back-to-top" title="回到頂部" onclick="window.scrollTo({top:0,behavior:'smooth'})">↑</button>

  <script>
    const backBtn = document.querySelector('.back-to-top');
    window.addEventListener('scroll',() => {
      if(window.scrollY > 320){
        backBtn.style.display='block';
      } else {
        backBtn.style.display='none';
      }
    });

    // 平滑錨點
    document.querySelectorAll('a[href^="#"]').forEach(a=>{
      a.addEventListener('click',e=>{
        const id = a.getAttribute('href');
        if(id.length>1){
          e.preventDefault();
          const target = document.querySelector(id);
          if(target){ target.scrollIntoView({behavior:'smooth',block:'start'}); }
        }
      });
    });
  </script>
</body>
</html>
